SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: dorightbythem1/9/2016 10:08:14 AM
1 Recommendation

Recommended By
sogwap1

  Read Replies (2) of 63278
 
Why did I choose Roche ?

1. It is the most interesting deal to be made and would combine an immunotherapy checkpoint inhibitor with an ADC namely IMMU-132.
2. Roche has the means to run multiple trials .
3. Roche remains one of two Biotech companies that Immunomedics has a quasi relationship with via the Karolinska Institute, the other being Bayer through the Algeta trial. Both strangely enough include pre-clinical trial with Dock-and-Lock (DNL) technology and epratuzumab (no update since July 24, 2012) and the other a clinical trial with epratuzumab, conjugated with Algeta's proprietary thorium-227 (no update since January 28, 2013) .

Problem ? You bet, but interesting even if IMMU gets taken out.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News